Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Safe-Blood

Financiado

A cost and time effective blood test to detect multiple bloodborne diseases

In the European Union alone, 15 million blood donations are collected annually, but supply of sufficient and safe donor blood remains a continuous struggle. Blood can save lives; however, it also carries the potential to transmit... ver más

28/02/2019

WWAMA DIAGNOSTICS...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

WAMA DIAGNOSTICS SWITZERLAND SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-02-28

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 70% 100%

2 Participantes

WWAMA DIAGNOSTICS (SWITZERLA...

50.00K€ | Lider

INDICAM TECHNOLOGIES

275.08K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 6 meses Fecha Inicio: 2018-08-10
Fecha Fin: 2019-02-28

Líder del proyecto

WAMA DIAGNOSTICS SWITZERLAND SA

TRL 4-5

Presupuesto del proyecto 71K€

Descripción del proyecto In the European Union alone, 15 million blood donations are collected annually, but supply of sufficient and safe donor blood remains a continuous struggle. Blood can save lives; however, it also carries the potential to transmit life-threatening infections. Potential donors are screened using a questionnaire aimed to identify risk carriers. As risk carriers do not equal disease carriers, thousands of potential donors are excluded to prevent one single case of a transfusion-transmitted disease. Subsequently, blood donations are screened for infectious diseases in the laboratory with one test for each disease. WAMA Diagnostics is a Swiss-founded company with the ambition to disrupt the in vitro diagnostics market with affordable and reliable tests to diagnose infectious diseases. WAMA has the expertise and technology to convert multiple tests into one single test, reducing time and money. WAMA is developing the Safe-Blood test to simultaneously screen for HIV, Hepatitis B, Hepatitis C, Syphilis, HTLV and Chagas in a single test. Our preliminary cost-benefit analysis demonstrates the potential to reduce the screening costs from €70 - €250 per donor to €15 per donor. 1,400 European blood donation banks are responsible for the collection of the 15 million blood donations per year. The global blood screening market is expected to grow from €1.3 billion in 2015 with a Compound Annual Growth Rate of 10.2% to €3.1 billion in 2024. The competition is offering solely monoplex tests: one test for one disease. There are currently no players on the blood screening market that use multiplex tests to screen for multiple diseases simultaneously, and the Safe-Blood test will hold a unique position in the market. WAMA will use the SMEi phase 1 funding to assess the feasibility and commercial potential of Safe-Blood via a user involvement study, a stakeholder engagement study, and a market study to identify the best business model to be applied in the EU.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores